Clinical Trials Browser

INDUSTRY × Interventional × tandutinib × Clear all

NCT00297921 2013-11-06

A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy

Phase 1/2 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00904852 2009-05-20

Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme

Phase 1 Withdrawn

Glioblastoma

NCT00064584 2009-03-24

Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML)

Phase 1 Completed

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00274248 2008-02-11

MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients With Newly Diagnosed Acute Myelogenous Leukemia

Phase 1 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute